Discuss any persistent GI distress with your provider
Key Differences Summary# Conclusion# Liraglutide represents a meaningful advancement over exenatide across glycemic control (LEAD-6 and DURATION-6 head-to-head superiority), weight management (only agent with FDA obesity approval among the two), cardiovascular outcomes (LEADER superiority vs EXSCEL non-inferiority), and tolerability (less persistent nausea, no injection site nodules, minimal immunogenicity)
Suboptimal Treatment Response with AOMs Once a treatment has been initiated, it is important to consider what to do in the event of a suboptimal treatment response
Additionally, nutrient deficiencies , food sensitivities and chronic infections are often present
Sanin Syed: Rochesters Leading GLP-1 Weight Loss Specialist When it comes to managing complex medical treatments like GLP-1 receptor agonist therapy, the expertise and credentials of your physician matter enormously
If weight regain starts, the doctor may review: Medication dose and adherence
)
